Overview

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2

Status:
Completed

Trial end date:
2017-07-15

Target enrollment:

Participant gender:

Summary

The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin
Metformin
Saxagliptin